Slide 1: Thyrocare - Presentation on Quarterly Results
Thyrocare® Think Thyroid. Think Thyrocare. October 28, 2020 I To, National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Sandra Kurla Complex, Dalal Street, Sandra (E), Mumbai - 400 051 Mumbai- 400 00 I Dear Sirs, Sub: Presentation on Quarterly Results for the q
Slide 2: Disclaimer
Thyrocare Technologies Limited Presentation – Q22021 Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements o
Slide 3: Key Highlights
Key Highlights Revenue from Standalone Quarterly revenue increased by 38% YoY and 173% QoQ operations Consolidated Quarterly revenue increased by 32% YoY and 172% QoQ • Q2 Pathology Revenue of Rs. 148.54 Crore, consists of Covid RTPCR Revenue of Rs. 47.7 Crore. • Pathology Revenue (excluding Covid R
Slide 4: Financial Performance - Thyrocare
Financial Performance - Thyrocare Thyrocare Technologies Limited Statement of Unaudited Standalone Financial Results (Rs. in crore, except per share data) Particulars Quarter ended Half Year ended 30.09.2020 % 30.09.2019 % 30.09.2020 % 30.09.2019 % Revenue from operations 148.54 107.89 202.94 208.39
Slide 5: Operational Performance - Thyrocare
Operational Performance - Thyrocare
Slide 6: Financial Performance - Nueclear
Financial Performance - Nueclear Nueclear Healthcare Limited Statement of Unaudited Standalone Financial Results (Rs. in crore, except per share data) Particulars Quarter ended Half Year ended 30.09.2020 % 30.09.2019 % 30.09.2020 % 30.09.2019 % Revenue from operations 4.71 8.61 6.57 18.08 Cost of Ma
Slide 7: Operational Performance - Nueclear
Operational Performance - Nueclear Centre Revenue (in crore) Apr-20 May-20 Jun-20 Jul-20 Aug-20 Sep-20 Total Navi Mumbai 0.09 0.13 0.13 0.18 0.25 0.25 1.02 Delhi 0.00 0.00 0.01 0.12 0.12 0.13 0.38 Hyderabad 0.01 0.00 0.02 0.15 0.20 0.31 0.69 Prabhadevi 0.10 0.13 0.23 0.17 0.24 0.29 1.16 Aurangabad 0
Slide 8: Consolidated Financial Performance - Thyrocare
Consolidated Financial Performance - Thyrocare Thyrocare Technologies Limited [Consolidated] Statement of Unaudited Consolidated Financial Results (Rs. in crore, except per share data) Particulars Quarter ended Half Year ended 30.09.2020 % 30.09.2019 % 30.09.2020 % 30.09.2019 % Revenue from operatio
Slide 9: YTD Updates
YTD Performance - Thyrocare YTD Updates Total Revenue from pathology business (including Covid RTPCR) – Rs. 202.94 Crore (Previous Year – Rs. 208.39 Crore). Total Revenue from Covid RTPCR – Rs. 71.01 Crore (35.1% of Total revenue from pathology business) Total non covid samples processed and r
Slide 10: Thank You
Thyrocare’ The Trust. The Truth. THANK YOU